These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8188400)

  • 1. Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention.
    Beccari M
    Int J Artif Organs; 1994 Jan; 17(1):5-13. PubMed ID: 8188400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Erythropoietin and hypertension].
    Frei U; Nonnast-Daniel B; Koch KM
    Klin Wochenschr; 1988 Sep; 66(18):914-9. PubMed ID: 3054276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin associated hypertension among pediatric dialysis patients.
    Komatsu Y; Ito K
    Adv Perit Dial; 1992; 8():448-52. PubMed ID: 1361845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of erythropoietin on blood pressure.
    Raine AE; Roger SD
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):76-83. PubMed ID: 1928084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Status epilepticus in chronically dialyzed patients treated with erythropoietin].
    Massetani R; Galli R; Calabrese R; Sartucci F; Rindi P; Severino Brandi L; Murri L
    Riv Neurol; 1991; 61(6):215-8. PubMed ID: 1813973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
    Yamakado M; Umezu M; Nagano M; Tagawa H
    Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seizures in haemodialysis patients treated with recombinant human erythropoietin.
    Edmunds ME; Walls J; Tucker B; Baker LR; Tomson CR; Ward M; Cunningham J; Moore R; Winearls CG
    Nephrol Dial Transplant; 1989; 4(12):1065-9. PubMed ID: 2517327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of recombinant human erythropoietin therapy on renal transplantation.
    Ettenger RB; Marik J; Grimm P
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):57-61. PubMed ID: 1928081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
    Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension following erythropoietin therapy in anemic hemodialysis patients.
    Buckner FS; Eschbach JW; Haley NR; Davidson RC; Adamson JW
    Am J Hypertens; 1990 Dec; 3(12 Pt 1):947-55. PubMed ID: 2127895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adverse effects of recombinant human erythropoietin therapy.
    Wong KC; Li PK; Lui SF; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(4):183-206. PubMed ID: 2088088
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
    Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
    Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
    Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.